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Background: A primary goal of recombinant human growth hormone therapy (GHT) in children is attaining normal
adult height. In this study, children with growth hormone deficiency (GHD) (including isolated idiopathic growth
hormone deficiency [IGHD] and multiple pituitary hormone deficiency [MPHD]), idiopathic short stature (ISS), and
Turner syndrome (TS) were evaluated for near-adult height (NAH) and percent achieving NAH within the normal
range after approximately 4 years of GHT.
Methods: Data from the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program were analyzed
for NAH from age at treatment start (ATS) (i.e., referral age as defined by age at enrollment in the study) to last
clinic visit using one of the following two criteria: 1) age ≥18 years, or 2) if male: ≥16 years and height velocity
(HV) <2 cm/year; if female: ≥15 years and HV <2 cm/year. All patients had a baseline height standard deviation
score (HSDS) ≤ −2, and either GHD (n = 201), ISS (n = 19), or TS (n = 41). The main outcome measures included HSDS
and corrected HSDS (HSDS-target HSDS) in response to GH treatment, and correlation of ATS with NAH HSDS.
Results: Mean (± SD) chronological and bone ages at baseline were 14.0 ± 2.1 years and 11.7 ± 2.0 years,
respectively, and mean GHT duration was 4.0 ± 1.6 years. Mean HSDS (baseline to NAH; GHD: −2.7 to −1.0; ISS: −2.8
to −1.4; TS: −3.0 to −1.8) and mean corrected HSDS (baseline to NAH; GHD: −2.1 to −0.3; ISS: −2.1 to −0.6; TS: −1.8
to −0.6) increased across diagnostic indications. Percentages of patients reaching near-adult HSDS > −2 were GHD:
87.6%; ISS: 78.9%; TS: 65.8%. Significant negative correlations were found between ATS and NAH HSDS when
analyzed by sex.
Conclusions: Despite a relatively advanced childhood age, the majority of GH-treated patients attained mean
near-adult HSDS within the normal range (HSDS > −2). Negative correlations of ATS with near-adult HSDS indicate
that an earlier age at treatment start would likely have resulted in greater adult height achieved in both male and
female patients.
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Treatment with recombinant human growth hormone
(GH) is indicated for children with short stature or
growth failure associated with a number of conditions in
which there is a deficiency of, or decreased responsive-
ness to, endogenous growth hormone. The use of GH is
approved by the US Food and Drug Administration for
the treatment of growth failure associated with growth
hormone deficiency (GHD), either isolated (IGHD) or
part of multiple pituitary hormone deficiency (MPHD),
and short stature associated with Turner syndrome (TS),
Noonan syndrome (NS), children born small for gesta-
tional age (SGA), short stature homeobox (SHOX) gene
haploinsufficiency, Prader-Willi syndrome (PWS), chronic
kidney disease (CKD), or idiopathic short stature (ISS) [1].
Treatment with GH has been shown to increase short-
term linear growth in children with various disorders
associated with growth failure; however, some of the
short-term clinical studies have shown varying treatment
outcomes [2-4]. A limited number of studies have investi-
gated the effects of long-term GH therapy (GHT) on the
adult height standard deviation score (HSDS) achieved
and whether the attained adult height was within the nor-
mal range.
Attaining adult height within the normal range is an
important treatment goal for GHT in children with
short stature or growth failure disorders, especially with
respect to the potential benefits in health-related quality
of life (HRQoL) and physical and psychosocial well-
being [5,6]. The adult height of patients treated with GH
is influenced by the height gained during the course of
therapy, the rate of bone maturation, and the onset
of puberty [7,8]. Longitudinal analyses of large data sets
of pediatric patients have consistently demonstrated that
the early initiation and appropriate duration of GH
treatment correlated significantly with the achievement
of near-normal adult height and greater improvements
in HSDS [2,9,10]. A multicenter, randomized, double-
blind clinical study of children with short stature who
were born SGA without signs of catch-up growth
showed that GH treatment to adult height was associ-
ated with a significant improvement in HRQoL and the
normalization of final height [5].
The American Norditropin Studies: Web-Enabled Re-
search (ANSWER) Program (utilizing NovoNet®, the
Novo Nordisk Web-based research platform) is an ob-
servational, noninterventional study evaluating the long-
term effectiveness and safety of Norditropin (somatropin
[recombinant DNA origin] injection, Novo Nordisk A/S,
Bagsvaerd, Denmark), hereafter referred to as GH, ther-
apy in pediatric and adult patients [11]. Enrollment in
this patient registry is solely at the discretion of the par-
ticipating physicians in patients for whom Norditropin®
is prescribed for treatment of appropriate conditions ofgrowth failure and short stature both within and outside
the Norditropin® label. Data from the ANSWER Pro-
gram have shown that children with IGHD, MPHD, ISS,
TS, NS, or SGA demonstrated an increase in HSDS
from baseline following 2 years of GH treatment [12,13].
Height velocity (HV) at 4 months of GHT and baseline
body mass index (BMI) SDS were significant predictive
factors in patients with GHD (including patients with
IGHD and MPHD) that positively correlated with a
change in HSDS (ΔHSDS) [13]. Baseline age, baseline
HSDS, and baseline serum insulin-like growth factor-1
(IGF-I) SDS were negatively correlated with ΔHSDS
[12,13]. No consistent effect of the sex of a patient on
response to GH treatment was observed in these
analyses from the ANSWER Program; however, a sex-
related effect on ΔHSDS was reported by Savendahl et al.
[14] in a combined analysis of short-term (2-year) GH
treatment responses in children with GHD, MPHD, or
SGA enrolled in the ANSWER Program and its European
counterpart, the NordiNet® International Outcome Study.
Greater growth responses were observed in younger,
prepubertal children in all diagnostic groups studied in a
report from the ANSWER Program, indicating that early
initiation of GH treatment is important for optimizing
linear growth response [12].
The principal aim of the current analysis of data from
the ANSWER Program registry was to evaluate the ef-
fects of GH treatment in previously untreated pediatric
patients with GHD, ISS, or TS with baseline HSDS ≤ −2
on near-adult height (NAH) outcomes. The effect of age
at the start of treatment on attainment of NAH was also
evaluated. NAH was evaluated only at the last clinic
visit when GH was discontinued, whereas HSDS was




The ANSWER Program is a non-interventional, observa-
tional study initiated in 2002 that has collected long-
term effectiveness and safety information on pediatric
patients treated with GH. Physicians participating in the
ANSWER Program provide updated patient histories
and physical examination data utilizing NovoNet®, an
online data-reporting tool. Institutional review board
(IRB) approval and patient informed consent are ob-
tained before study enrollment, which is at the discre-
tion of participating physician investigators. Pediatric
patients were included in the current analyses if they
were aged <18 years and GHT-naïve at the time of en-
rollment, had a baseline HSDS that met criteria for short
stature (≤ − 2), and had attained adult height or NAH at
their final clinic visit. Height velocity was used as a
criterion for near adult height for boys between 16
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clusive) and 18 years of age. In order to calculate height
velocity, a height measurement had to have been taken
between the minimum interval of 273 and the maximum
interval of 548 days before the last visit date. The previ-
ous height assessment nearest to 1 year (365 days) prior
to the last visit date was used. Height velocity was annu-
alized by calculating the change in height per day and
multiplying by 365.25 days. Patients were determined to
have reached NAH according to either one of the
following two criteria: 1) age at last visit was ≥18 years,
or 2) for males <18 years, if their age at last visit
was ≥16 years and HV <2 cm/year; or for females <
18 years, if their age at last visit was ≥15 years and
HV <2 cm/year. The rationale for using the first NAH
criterion of ≥18 years of age was to capture patients who
had a limited frequency of clinic visits prior to the last
clinic visit that prevented calculation of HV but whose
age would be consistent with completion or near com-
pletion of statural growth. Patients identified using HV
and age criteria had sufficient visit frequency from which
to assess HV consistent with NAH. As noted in previous
publications from the ANSWER Program pediatric pa-
tients are generally excluded from analysis if baseline
chronologic age (CA) was <1 year or >18 years, or if
baseline values of key variables were missing or deemed
inconsistent or implausible (e.g., lack of height informa-
tion at baseline; baseline height <35 cm or >200 cm;
baseline HSDS < −5 or > +2) [13,15]. The current study
assessed children with GHD (patients with IGHD and
MPHD), ISS, and TS who reached NAH after treatment
with GH. Data were collected from clinic visits within a ±3-
month window around each time point (i.e., year 1, year 2,
NAH [i.e., last visit]) and growth rates were annualized
based on the actual interval between measurements.Baseline characteristics and measurement of GH
treatment effects
Baseline demographics and patient characteristics across
all indications in GH-naïve patients were obtained just
prior to the start of GH treatment (i.e., at time of enroll-
ment in the registry). Baseline variables at enrollment in-
cluded sex, CA, bone age (BA), body weight, and height
[16]. Other baseline measurements were BA/CA ratio,
HSDS, target HSDS, corrected HSDS (HSDS minus tar-
get HSDS), predicted HSDS based on predicted adult
height calculated using the Bayley-Pinneau method [17],
serum levels of IGF-I (ng/mL) and determination of
IGF-I SDS, peak stimulated serum GH concentration
(ng/mL), BMI (kg/m2), BMI SDS, and initial GH dose
(mg/kg/day). At subsequent annual clinic visits, GH
dose was reported along with measurements of height,
weight, CA, BA, serum IGF-I concentration, and BMI.Variables and statistical analyses
The following key variables were determined at year 1,
year 2, and NAH (i.e., last clinic visit): mean HSDS,
mean corrected HSDS, mean change in HSDS (ΔHSDS),
BA/CA ratio, IGF-I SDS, and BMI SDS. The percentage
of patients who achieved a HSDS at NAH within the
normal range (HSDS > −2) was also determined. Height
SDS and BMI SDS were calculated using standard refer-
ence data developed by the United States Centers for
Disease Control and Prevention [18]. Baseline demo-
graphic characteristics were summarized using descrip-
tive statistics. Target height was evaluated using the
mean height of the patient’s two parents plus 6.5 cm for
male patients or minus 6.5 cm for female patients [19].
Corrected HSDS was calculated as the difference be-
tween HSDS determined at a given time point and the
target HSDS. ΔHSDS was calculated as the difference
between the HSDS at baseline and at year 1, year 2, and
NAH. All IGF-I values were measured locally and en-
tered into the database. Transformation of IGF-I data
into IGF-I SDS was based on the age- and sex-related
normative reference values of Brabant et al. [20]. The
correlation between age at GH treatment start (ATS)
and near-adult HSDS was evaluated by estimating Pear-
son’s correlation coefficient (R) between the 2 variables.
Near-adult HSDS was analyzed using an analysis of co-
variance model (ANCOVA) with sex as the fixed effect
and referral age as the covariate. A regression model was
applied to analyze the relationship between ATS (i.e., re-
ferral age as defined by age at enrollment in the study)
and near-adult HSDS for all patients combined with
GHD, ISS, and TS according to sex. Values are reported
as mean and standard deviation (±SD) for descriptive
statistics or mean and standard error (±SE) for compara-
tive statistics. All differences detected from statistical
analyses were considered significant at P values <0.05.
Results
Patient demographics and baseline characteristics
A total of 261 GH-naïve patients who were diagnosed
with GHD (n = 201), ISS (n = 19), or TS (n = 41), and
had achieved NAH, were included in the analyses. This
total patient number consisted of 178 patients identified
according to the age criterion (≥18 years) and 83 pa-
tients identified according to age and HV criteria for
NAH (20 males, 63 females). Demographics and baseline
characteristics for the overall study population and for
each diagnostic indication cohort are presented in
Table 1. Overall, the study population consisted of 173
males (66.3%) and 88 females (33.7%), including 41 fe-
males with TS. The mean referral age was 14.7 ± 1.6 years
among males and 12.8 ± 2.3 years among females. The
mean ± SD baseline CA across all indications (N = 261)
was 14.0 ± 2.1 years (14.9 ± 1.5 years among patients
Table 1 Baseline demographics, characteristics, and GH treatment duration
Characteristic Overall GHD ISS TS
(N = 261) (n = 201) (n = 19) (n = 41)
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
Sex, M/F 173/88 158/43 15/4 0/41
Chronologic age (CA), y
All NAH criteria 261 14.0 ± 2.1 201 14.2 ± 1.9 19 14.0 ± 1.9 41 13.1 ± 2.5
age >18 y 178 14.9 ± 1.5 149 14.9 ± 1.5 13 14.6 ± 1.4 16 14.9 ± 2.2
male, age >16 y, 20 12.7 ± 1.9 18 12.5 ± 1.9 2 14.6 ± 0.06 – –
HV < 2 cm/y
female, age >15 y, HV <2 cm/y 63 12.2 ± 2.1 34 12.4 ± 2.1 4 11.9 ± 2.3 25 11.9 ± 2.0
Bone age (BA), y 215 11.7 ± 2.0 169 11.9 ± 1.9 16 11.6 ± 2.2 30 11.0 ± 2.2
BA/CA ratio 215 0.85 ± 0.08 169 0.85 ± 0.08 16 0.84 ± 0.08 30 0.84 ± 0.09
HSDS
All NAH criteria 261 −2.8 ± 0.6 201 −2.7 ± 0.5 19 −2.8 ± 0.6 41 −3.0 ± 0.6
age >18 y 178 −2.8 ± 0.6 149 −2.7 ± 0.6 13 −2.9 ± 0.7 16 −2.9 ± 0.7
male, age >16 y, HV < 2 cm/y 20 −2.5 ± 0.4 18 −2.5 ± 0.4 2 −2.6 ± 0.0 – –
female, age >15 y, HV <2 cm/y 63 −2.8 ± 0.5 34 −2.7 ± 0.5 4 −2.6 ± 0.3 25 −3.0 ± 0.6
Target HSDS 222 −0.3 ± 0.8 171 −0.3 ± 0.8 18 −0.7 ± 0.7 33 0.2 ± 0.9
Corrected HSDS 221 −2.1 ± 4.1 169 −2.1 ± 4.0 18 −2.1 ± 0.7 34 −1.8 ± 5.3
Predicted HSDS* 186 −1.4 ± 1.1 143 −1.2 ± 1.0 13 −1.6 ± 1.1 30 −2.1 ± 0.9
IGF-I SDS 187 −2.6 ± 1.60 152 −2.7 ± 1.60 12 −2.3 ± 1.81 23 −1.7 ± 1.22
BMI, kg/m2 260 19.9 ± 4.5 201 19.7 ± 4.5 18 18.1 ± 2.8 41 21.4 ± 4.9
BMI SDS 260 −0.21 ± 1.38 201 −0.32 ± 1.44 18 −0.68 ± 1.05 41 0.53 ± 0.90
Peak GH, ng/mL 166 6.9 ± 5.7 148 5.5 ± 2.8 14 20.3 ± 9.7 4 10.9 ± 8.7
Initial GH dose, mg/kg/d 259 0.048 ± 0.012 199 0.047 ± 0.013 19 0.050 ± 0.006 41 0.052 ± 0.008
Treatment duration, y 261 4.0 ± 1.6 201 3.9 ± 1.5 19 3.9 ± 1.5 41 4.4 ± 2.0
Abbreviations: BMI body mass index, GH growth hormone, GHD growth hormone deficiency, HSDS height standard deviation score, IGF-I insulin-like growth
factor-1, ISS idiopathic short stature, M/F male/female, TS Turner syndrome, SDS standard deviation score; y, years.
Predicted HSDS was calculated by the Bayley-Pinneau method [17] using a child’s current height, sex, chronological age, and bone age.
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among male patients identified according to the HV
criterion, and 12.2 ± 2.1 years among female patients
identified according to the HV criterion). Mean ± SD BA
across indications at baseline was 11.7 ± 2.0 years (N =
215), approximately 2 years behind CA; this was also
reflected in a baseline BA/CA ratio <1 across all patient
cohorts (0.85 ± 0.08, N = 215).
At baseline (Table 1), the mean ± SD stimulated peak
serum GH concentration (ng/mL) was 5.5 ± 2.8 in patients
with GHD, 20.3 ± 9.7 in patients with ISS, and 10.9 ± 8.7
in females with TS. Mean ± SD IGF-I SDS was −2.7 ± 1.60
in patients with GHD, −2.3 ± 1.81 in those with ISS,
and −1.7 ± 1.22 in females with TS.
The mean ± SD duration in years of GH treatment by
indication (Table 1) was 3.9 ± 1.5 for both GHD and ISS
groups, and 4.4 ± 2.0 in females with TS. The mean ini-
tial GH doses (mg/kg/d) administered to each patient
cohort at treatment start (Table 1) were 0.047 ± 0.013(n = 199) in patients with GHD, 0.050 ± 0.006 (n = 19)
in those with ISS, and 0.052 ± 0.008 (n = 41) in females
with TS.
Analysis of auxological measurements
Height standard deviation scores
The mean ± SD baseline HSDS was −3.0 ± 0.6 (n = 41)
for patients with TS, −2.8 ± 0.6 (n = 19) for patients with
ISS, and −2.7 ± 0.5 (n = 201) for patients with GHD.
Target HSDS (mean ± SD) at baseline was −0.7 ± 0.7
(n = 18) for patients with ISS, −0.3 ± 0.8 (n = 171) for pa-
tients with GHD, and +0.2 ± 0.9 (n = 33) for patients
with TS (Table 1). Mean ± SE HSDS gradually increased
over time for the overall study population from −2.8 ±
0.04 (n = 261) at baseline to −1.1 ± 0.06 (n = 261) at
NAH (Figure 1A). Patients with GHD, ISS, and TS expe-
rienced increases in mean ± SE HSDS from baseline to
NAH (near-adult HSDS: GHD, −1.0 ± 0.065, n = 201;




































































Baseline Year 1 Year 2 NAH
Figure 1 HSDS, ΔHSDS and corrected HSDS in patients from baseline to near-adult height at the last visit. (A) Mean HSDS at baseline,
year 1, year 2, and NAH at the last clinic visit. (B) Mean ΔHSDS (HSDS-target HSDS) at year 1, year 2, and NAH at the last visit. (C) Mean corrected
HSDS at baseline, year 1, year 2, and NAH at the last visit. GHD: growth hormone deficiency; HSDS: height standard deviation score; ISS: idiopathic
short stature; NAH: near-adult height; TS: Turner syndrome.
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HSDS (Figure 1C) increased with GH treatment
(ΔHSDS at NAH: GHD, 1.74 ± 0.06, n = 201; ISS, 1.45 ±
0.19, n = 19; TS, 1.19 ± 0.10, n = 41; baseline correctedHSDS: GHD, −2.1 ± 0.31, n = 169; ISS, −2.1 ± 0.16, n =
18; TS, −1.8 ± 0.92, n = 34; corrected HSDS at NAH:
GHD, −0.3 ± 0.31, n = 169; ISS, −0.6 ± 0.23, n = 18;
TS, −0.6 ± 0.96, n = 34). The mean ± SD GH dose (mg/kg/
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0.050 ± 0.018, n = 199; ISS: 0.052 ± 0.012, n = 19; and TS:
0.053 ± 0.011, n = 41) had not changed markedly from
treatment start. The majority of patients in each indication
achieved heights in the normal range (> − 2 HSDS) by the
last visit: 87.6%, 78.9%, and 65.8% of GHD, ISS and TS
patients, respectively (83.5% of patients overall).Age at treatment start and near-adult HSDS
When evaluating the total patient population, no signifi-
cant correlation was found between ATS and near-adult
HSDS (Pearson’s correlation coefficient, R = −0.072, P =
0.25). The ANCOVA model with sex as the fixed effect
and referral age as the covariate confirmed that sex (P <
0.001) and referral age (P < 0.001) were statistically sig-
nificant, indicating a relationship between near-adult
HSDS, referral age and sex. When analyzing this rela-
tionship separately by patient sex, significant negative
correlations were found for both males and females
(including patients with TS): males, Pearson’s correlation
coefficient, R = −0.21, P = 0.006; females, Pearson’s cor-
relation coefficient, R = −0.25, P = 0.017 (Figure 2).Figure 2 Effects of age at treatment start on adult HSDS by
sex. Correlation between ATS and adult HSDS (P < 0.001). The effects
of ATS on adult HSDS vary depending on sex (P < 0.001; ANCOVA).
ATS: age at treatment start; HSDS: height standard deviation score.
Top line: Regression of near-adult HSDS against ATS for males.
Bottom line: Regression of near-adult HSDS against ATS for females.IGF-I and BMI
The attainment of NAH across patient cohorts was par-
alleled by increases in mean ± SE IGF-I SDS (Figure 3A)
to within the normal reference range across all indica-
tions (GHD at baseline: −2.74 ± 0.130, n = 152; GHD at
NAH: 0.27 ± 0.172, n = 193; ISS at baseline: −2.29 ±
0.522, n = 12; ISS at NAH: 0.15 ± 0.687, n = 16; TS at
baseline: −1.72 ± 0.255, n = 23; TS at NAH, 1.05 ± 0.333,
n = 35). Mean ± SE BMI SDS (Figure 3B) showed
minimal change for each indication over time during
GH treatment (GHD at baseline: −0.32 ± 0.101, n =
201; GHD at NAH: −0.11 ± 0.097, n = 201; ISS at base-
line: −0.68 ± 0.246, n = 18; ISS at NAH: −0.20 ± 0.230,
n = 19; TS at baseline: 0.53 ± 0.141, n = 41; TS at NAH:
0.66 ± 0.135, n = 41). Mean ± SE BA/CA ratio remained
stable over time during GH treatment across all indi-
cations (GHD at baseline: 0.85 ± 0.006, n = 169; GHD
at NAH: 0.86 ± 0.006, n = 197; ISS at baseline: 0.84 ±
0.019, n = 16; ISS at NAH: 0.88 ± 0.021, n = 19; TS at
baseline: 0.84 ± 0.016, n = 30; TS at NAH: 0.82 ± 0.014,
n = 39).
Discussion
The results of this analysis of GH treatment in pediatric
patients with GHD, ISS, or TS demonstrated that GH-
naïve children with short stature achieved a mean NAH
within the normal reference range. Mean HSDS, cor-
rected HSDS, and IGF-I SDS all improved over time
with GH treatment, and the majority of patients were
within the normal reference range (> − 2 HSDS) at the
time of NAH. Overall, 83.5% of the study population
had attained normal height (HSDS > −2) over the dur-
ation of GH treatment (mean duration, years: GHD 3.9;
ISS 3.9; TS 4.4). It is possible that the results were biased
towards good responders, since poor responders may
have withdrawn from the study or stopped GH treat-
ment before reaching adulthood. The proportion of TS
patients who attained normal height (66%) in this study
was smaller compared with those of the other indica-
tions studied (79-88%). The reasons for this finding are
unclear; nevertheless, this result is consistent with find-
ings from a previous analysis of patients with TS from
the ANSWER program [21].
At baseline, the mean ± SD overall age was 14.0 ±
2.1 years (12.8 years in females and 14.7 years in males),
which was nearly 4 years older than the mean age of
pediatric patients typically enrolled in the ANSWER
Program (10.5 ± 4.0 years). Consequently, this analysis of
patients who attained NAH was skewed toward children
who were older at the time of GHT initiation, and thus
may not be representative of the overall population in
the ANSWER Program. The short duration of the Pro-
gram (initiated in 2002) could have contributed to a se-
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Overall GHD ISS TS
Figure 3 IGF-I SDS and BMI SDS from baseline to near-adult height at the last visit. (A) IGF-I SDS at baseline, year 1, year 2, and NAH at the
last clinic visit. (B) BMI SDS at baseline, year 1, year 2, and NAH at the last visit. BMI: body mass index; GHD: growth hormone deficiency; IGF-1:
insulin-like growth factor-1; ISS: idiopathic short stature; NAH: near-adult height; SDS: standard deviation score; TS: Turner syndrome. Error bars
represent standard error (SE).
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18 years as of the cut-off date for this current analysis.
The older age at baseline in this subgroup may have re-
sulted in an underestimation of the overall adult height
achievable by all patients treated with GH. Previous
studies from the ANSWER Program have shown that
earlier age at GH treatment initiation is associated with
greater height gain [12,13], reinforcing the importance
of early referral for GHT in appropriate patients when
growth failure or short stature is recognized. From the
results of this analysis of the changes in mean HSDS and
corrected HSDS from baseline to NAH, it would appear
that these patients did experience a beneficial response
to GH treatment. Sex was confirmed to be a statistically
significant factor for NAH outcome, possibly due to the
difference in referral age between sexes (females were
younger than males). The significant negative correlation
observed between ATS and near-adult HSDS for both
sex subgroups indicates that, although a beneficial effectmay be observed when GH therapy is initiated at an
older childhood age, greater near-adult HSDS can be ex-
pected if these patients had started GHT at a younger
age. Healthcare providers should therefore be aware of
the potential limitations of this treatment among pa-
tients of a relatively advanced age. The correlation re-
sults of this study in relatively older children are
consistent with recently published analyses of GH treat-
ment on increasing linear growth to NAH or final height
in younger children with IGHD or MPHD from other
large patient databases [22-26]. This has also been
shown in patients from other diagnostic groups, such as
Noonan syndrome. Recently published ANSWER Pro-
gram data on patients with Noonan syndrome with a
mean referral age of 9 years showed that baseline age
was negatively correlated with ΔHSDS after 1 or 2 years
of GH treatment, indicating that older baseline ATS
resulted in lower ΔHSDS [27-29]. In the present study,
analysis of the relationship between age at initiation of
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and TS showed significant negative correlations,
which is consistent with previous reports [13,15,28].
The results of the current analysis are among the first
to describe the long-term effects of GH treatment, in-
cluding an increase in HSDS at the time of NAH, in
children who initiated GHT at an older age.
The effect of GH treatment on the BA/CA ratio was
relatively small, and BA/CA remained <1 for patients
across all indications over time. This suggests that, al-
though GH treatment exerted positive effects on linear
growth in this older pediatric patient population, there
was a minimal effect on bone maturation relative to CA.
The effect of pubertal stage in these patients was not an-
alyzed and cannot be ruled out as a contributing factor.
Also, the mean BA/CA ratio in the range of 0.82 to 0.88
indicates that, on average, a small amount of additional
growth would have remained in some patients, consist-
ent with near rather than final peak adult height.
Mean IGF-I SDS increased in patients with GHD, ISS,
and TS at year 1 of GH treatment, remaining relatively
stable thereafter. The difference in mean IGF-I SDS
(GHD - ISS) was only −0.45 at baseline and 0.12 at
NAH. From baseline to NAH, BMI SDS showed variable
increases, but remained stable, during GHT among the
diagnostic groups. This occurred in parallel with sus-
tained increases in HSDS and corrected HSDS in each
group during GH treatment. The negative mean BMI
SDS at baseline observed in patients with ISS in the
present study might suggest a degree of relative nutri-
tional deficiency in these individuals that improved over
time. Recent results published from the ANSWER Pro-
gram registry indicated that for patients with GHD, a
higher baseline BMI was positively correlated with the
response to GH [13]. The association of BMI on GH re-
sponse may reflect, in part, the importance of nutrition
or nutritional status for optimizing outcomes in GH-
treated patients [12,13,30,31].Conclusions
In conclusion, long-term GH therapy in GH-naïve
pediatric patients with GHD, ISS, or TS resulted in in-
creases in HSDS and corrected HSDS from baseline to
NAH despite their older age at the start of GHT. Al-
though the results of this study demonstrate good NAH
outcomes in children with short stature or growth fail-
ure who initiated GH treatment at an older age, the
negative correlations of ATS with near-adult HSDS
when analyzed by sex indicate that earlier recognition
and referral for growth failure or short stature, and ef-
forts to start GH treatment at a younger age, would
most likely have resulted in greater gains in height and
an increase in adult HSDS.Abbreviations
ATS: Age at treatment start; BA: Bone age; BMI: Body mass index;
CA: Chronological age; GH: Growth hormone; GHD: Growth hormone
deficiency; GHT: Growth hormone therapy; HSDS: Height standard deviation
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